Results 171 to 180 of about 4,853 (196)
Some of the next articles are maybe not open access.
An indirubin derivative, E804, exhibits potent angiosuppressive activity
Biochemical Pharmacology, 2012Angiogenesis, the development of neovessels from pre-existing vessels, is obligatory for solid tumors survival, growth, invasion, and metastasis. Many anti-angiogenic agents are small molecules originated from natural sources. Recently, angiosuppressive effects of indirubin and its derivatives, the active components in indigo-producing herbs, have been
Yuk-Kit, Chan +7 more
openaire +2 more sources
Synthesis and cytotoxicity of novel indirubin-5-carboxamides
Bioorganic & Medicinal Chemistry, 2010Indirubins have been reported to act as potent inhibitors of protein kinases relevant to tumorigenesis and of tumor cell growth, but their development to antitumor drugs suffer from their poor water solubility. We synthesized a novel class of indirubin derivatives, indirubin-5-carboxamides, carrying amide substituents with basic centers. Quaternization
Xinlai, Cheng +4 more
openaire +2 more sources
Novel Synthesis of 4- or 6-Substituted Indirubin Derivatives
Synthetic Communications, 2010A simple and convenient route for synthesis of a series of 4- or 6-substituted indirubin derivatives by oxidation and subsequent condensation of indoxyl and isatin is described. Acidic reaction conditions are crucial to the condensation of 4-substituted derivatives, whereas for the condensation of 6-substituted derivatives, both acidic and basic ...
Aiying Zhang +4 more
openaire +2 more sources
First synthesis of indirubin N-glycosides (red sugars)
Tetrahedron Letters, 2006AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Stefanie Libnow +3 more
openaire +1 more source
Leukemia Research, 2013
Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment.
Woo-Seok, Kim +7 more
openaire +2 more sources
Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment.
Woo-Seok, Kim +7 more
openaire +2 more sources
HYDROXYLATED INDIRUBIN DERIVATIVES
2004The present invention relates to hydroxylated indirubin derivatives having the formula (I) wherein the group R represents a straight-chain or branched-chain alkyl group or a straight chain or branched-chain alkoxy group each having 1 to 18 carbon atoms, the group R' represents H, a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms
EISENBRAND GERHARD, HIPPE FRANKIE
openaire +1 more source
[Synthesis of some halogenated indirubin derivatives].
Yao xue xue bao = Acta pharmaceutica Sinica, 1990Indirubin has been used clinically to treat chronic granulocytic leukemia, but poor solubility limited its absorption in the body. In order to reduce its side effect and raise its therapeutic effect on chronic granulocytic leukemia, six halogen-substituted derivatives were synthesized.
Y C, Gu +4 more
openaire +1 more source
Molecular targets of indirubins
Int. Journal of Clinical Pharmacology and Therapeutics, 2005S, Jakobs +3 more
openaire +2 more sources

